Calciphylaxis Market Report 2026

Calciphylaxis Market Overview

• Calciphylaxis market size has reached to $3.54 billion in 2025 • Expected to grow to $5.55 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Chronic Kidney Disease Prevalence Drives Growth In Related Health Complications • Market Trend: Innovative Enzyme Replacement Therapy Advancements In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Calciphylaxis Market?

Calciphylaxis refers to a rare, serious condition characterized by the calcification of small blood vessels, leading to skin necrosis and severe pain. It is used for studying vascular calcification disorders and developing targeted treatments to improve wound healing and pain management in affected patients. The main types of calciphylaxis are non-uremic calciphylaxis, ulcers and wounds, and debridement of wounds. Non-uremic calciphylaxis is a rare form of calciphylaxis that occurs in patients who do not have chronic kidney disease or are not on dialysis. It is characterized by the abnormal deposition of calcium in the small blood vessels, which leads to tissue damage, pain, and necrosis. Treatment options include drug therapy and hyperbaric calciphylaxis therapy, while diagnosis involves deep skin biopsies, blood tests, and imaging. Key end users include hospitals, clinics, home care, and ambulatory centers.

What Is The Calciphylaxis Market Growth Forecast?

The calciphylaxis market size is expected to see strong growth in the next few years. It will grow to $5.55 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing research into targeted calcification therapies, rising adoption of personalized treatment protocols, expansion of multidisciplinary care models, growing investment in rare disease research, increasing use of advanced wound healing technologies. Major trends in the forecast period include increasing focus on early diagnosis of vascular calcification, rising use of advanced imaging techniques, growing integration of multimodal treatment approaches, expansion of specialized wound care protocols, enhanced emphasis on pain management strategies.

Global Calciphylaxis Market Segmentation

1) By Type: Non-Uremic Calciphylaxis, Ulcers And Wounds 2) By Diagnosis: Skin Biopsy, Laboratory Tests, Imaging Studies, Clinical Assessment and Risk Evaluation 3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Care Centers, Homecare Settings Subsegments: 1) By Non-Uremic Calciphylaxis: Vascular Calcification, Soft Tissue Calcification, Cutaneous Manifestations 2) By Ulcers and Wounds: Skin Ulcers, Ischemic Wounds, Necrotic Ulcers

What Are The Drivers Of The Calciphylaxis Market?

The rising incidence of chronic kidney disease (CKD) is expected to propel the growth of the calciphylaxis market going forward. Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood, leading to potential kidney failure over time. The rising incidence of chronic kidney disease is attributed to factors such as an aging population, increasing prevalence of diabetes and hypertension, unhealthy lifestyle choices, and a lack of early detection and management of kidney-related conditions. Calciphylaxis serves as a critical indicator of severe vascular complications in chronic kidney disease (CKD), highlighting the need for early intervention and improved management of mineral imbalances to prevent tissue necrosis and associated morbidity. For instance, in June 2023, according to the Kidney Research UK, a UK-based, charity dedicated to funding research into kidney disease, by 2033, the population affected by CKD stages 3–5 is expected to rise to around 3.9 million. Therefore, the rising incidence of chronic kidney disease (CKD) is driving the growth of the calciphylaxis industry. The increasing prevalence of obesity is expected to propel the growth of the calciphylaxis market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that increases the risk of various health issues, such as heart disease, diabetes, and hypertension. The increasing prevalence of obesity is attributed to factors such as sedentary lifestyles, high-calorie diets, genetic predisposition, and limited access to healthy food options. Calciphylaxis risk increases with obesity due to metabolic dysfunction, chronic inflammation, and vascular calcification, which worsen calcium-phosphate imbalance and endothelial damage, especially in individuals with chronic kidney disease. For instance, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-government unit, in 2023–2024, about 64.5% of adults (18+) in England were estimated to be either overweight or living with obesity, this is slightly up from 64.0% in the previous period (2022–2023). Therefore, the increasing prevalence of obesity is driving growth of calciphylaxis industry.

Key Players In The Global Calciphylaxis Market

Major companies operating in the calciphylaxis market are Hope Pharmaceuticals Ltd, Sanofi S.A., Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca plc, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Johnson And Johnson, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Ipsen SA, Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, Horizon Therapeutics plc

Global Calciphylaxis Market Trends and Insights

Major companies operating in the calciphylaxis market are focusing on developing innovative therapies, such as enzyme replacement therapy, to improve treatment outcomes and reduce the severity of the condition. Enzyme replacement therapy (ERT) is a medical treatment that involves replacing a missing or deficient enzyme in the body. It is typically used to treat rare genetic disorders, where the body cannot produce a specific enzyme necessary for normal cell function. For instance, in October 2024, Inozyme Pharma Inc., a US-based biopharmaceutical company, announced positive interim results from its Phase 1 SEAPORT 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients. The trial's interim data highlights the potential of INZ-701 in restoring enzyme activity crucial for preventing abnormal mineralization, a key factor in severe rare diseases. It is designed as an enzyme replacement therapy targeting ENPP1 and ABCC6 deficiencies, which are associated with pathological calcium buildup in blood vessels and tissues.

Regional Outlook

North America was the largest region in the calciphylaxis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Calciphylaxis Market?

The calciphylaxis market consists of revenues earned by entities by providing services such as chronic care management, nutritional counselling and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis market also includes sales of dialysis equipment, phosphate binders, vitamin k2 supplements, and wound care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Calciphylaxis Market Report 2026?

The calciphylaxis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.